Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 15, 2020
- Accepted in final form January 5, 2021
- First Published March 16, 2021.
Author Disclosures
- Tomas Uher, MD, PhD,
- Jan Krasensky, MS (jan.krasensky{at}vfn.cz),
- Charles Malpas, MPsych, PhD (charles.malpas{at}unimelb.edu.au),
- Niels Bergsland, MS, PhD (npbergsland{at}bnac.net),
- Michael G. Dwyer, MS, PhD (mgdwyer{at}bnac.net),
- Eva Kubala Havrdova, MD, PhD (eva.havrdova{at}gmail.com),
- Manuela Vaneckova, MD, PhD (man.van{at}post.cz),
- Dana Horakova, MD, PhD (dana.horak{at}post.cz),
- Robert Zivadinov, MD, PhD (rzivadinov{at}bnac.net) and
- Tomas Kalincik, MD, PhD (tomas.kalincik{at}unimelb.edu.au)
- Tomas Uher, MD, PhD,
Sanofi - advisory board 1/2020
NONE
Financial support for conference travel and speaker honoraria from Biogen Idec, Novartis, Roche, Sanofi and Merck Serono.
Activitas Nervosa Superior: Associate Editor from 2018 Journal of Neuroimaging: Editorial Board from 2020 Frontiers In Neurology: Review Editor from 2020 Frontiers In Behavioral Neuroscience: Review Editor from 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen Sanofi (GZ-2017-11718)
NONE
Charles University Grant Agency (GAUK) Czech Ministry of Education project Progres Czech Ministry of Health project
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jan Krasensky, MS (jan.krasensky{at}vfn.cz),
NONE
NONE
Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Charles Malpas, MPsych, PhD (charles.malpas{at}unimelb.edu.au),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Niels Bergsland, MS, PhD (npbergsland{at}bnac.net),
NONE
NONE
NONE
1) Journal of Neuroimaging, Section editor for multiple sclerosis, 2018-present 2) PLOS ONE, Academic Editor, 2018-present 3) Journal of Magnetic Resonance Imaging, Associate Editor, 2018-present 4) Frontiers in Neurology, Associate Editor, 2020-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael G. Dwyer, MS, PhD (mgdwyer{at}bnac.net),
NONE
NONE
NONE
Assistant Editor, Journal of Neuroimaging
NONE
NONE
NONE
(1) Protembis GmbH (2) EMD Serono (3) Keystone Heart
NONE
NONE
NONE
(1) Novartis (2) Celgene (3) Protembis (4) Keystone Heart (5) Bristol Meyers Squibb
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eva Kubala Havrdova, MD, PhD (eva.havrdova{at}gmail.com),
1. Biogen 2. Novartis 3. Genzyme 4. Actelion 5. Celgene
NONE
1. Biogen 2. Novartis 3. Celgene 4. Genzyme 5. Actelion 6. Roche 7. Merck Serono
NONE
NONE
NONE
NONE
1. Biogen 2. Novartis 3. Celgene 4. Genzyme 5. Actelion 6. Roche 7. Merck Serono
NONE
NONE
NONE
NONE
1. European Commission Grant: ABIRISK - IMI (2012-2016), investigator 2. Czech Ministry of Education: PROGRES Q27/LF1 (2017- 2022), investigator
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen - Expert witness, 2019
- Manuela Vaneckova, MD, PhD (man.van{at}post.cz),
NONE
NONE
Biogen Idec, Novartis,Teva, Roche, Genzyme
NONE
NONE
NONE
NONE
Biogen Idec
NONE
NONE
NONE
Biogen Idec
Czech Ministries of Health - RVO-VFN64165
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Dana Horakova, MD, PhD (dana.horak{at}post.cz),
NONE
NONE
Dr. Horakova received compensation for travel, speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Roche, and Sanofi.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Support for research activities from Biogen Idec.
Supported by Czech Ministries of Education and Health [PRVOUK-P26/LF1/4].
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Robert Zivadinov, MD, PhD (rzivadinov{at}bnac.net) and
R Zivadinov received personal compensation from Genzyme-Sanofi, Celgene and Novartis for serving on scientific advisory board.
NONE
R Zivadinov received personal compensation from EMD Serono, Inc., Novartis, Sanofi-Genzyme,Celgene for speaking
NONE
NONE
NONE
NONE
R Zivadinov received personal compensation from EMD Serono, Inc., Novartis, Keystone Heart, Sanofi-Genzyme for consulting fees.
R Zivadinov received personal compensation from EMD Serono, Inc., BMS, Novartis, Sanofi-Genzyme for speaking
NONE
NONE
Dr. Zivadinov: financial support for research activities from EMD Serono, Inc., Novartis, Sanofi-Genzyme,Mapi Pharma, Celgene and Protembis, Keystone Heart.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tomas Kalincik, MD, PhD (tomas.kalincik{at}unimelb.edu.au)
(1) chair of the MSBase Scientific Leadership Group, (2) Novartis, (3) Merck, (4) Biogen, (5) Roche, (6) Genzyme-Sanofi, (7) Celgene
NONE
(1) Novartis, compensation for travel and speaker honoraria (2) Biogen, compensation for travel and speaker honoraria (3) Genzyme-Sanofi, compensation for travel and speaker honoraria (4) Teva, speaker honoraria (5) Merck, compensation for travel and speaker honoraria (6) WebMD Global, speaker honoraria (7) Roche, speaker honoraria (8) BioCSL, speaker honoraria
(1) Multiple Sclerosis Journal, editorial board member, since 2018 (2) CNS Drugs, editorial board member, since 2020 (3) Neurology and Clinical Practice, editorial board member, since 2020 (4) BMC Neurology, associate editor 2017-2018 (5) Frontiers in Neurology, reviewer editor 2017-2018
NONE
NONE
NONE
NONE
(1) Novartis, (2) Biogen, (3) Genzyme-Sanofi, (4) Teva, (5) Merck, (6) WebMD Global, (7) Roche, (8) BioCSL, (9) Roche, (10) BMS/Celgene
NONE
NONE
(1) Biogen, (2) Merck, (3) BMS/Celgene
NONE
(1) University of Melbourne
(1) National Health and Medical Research Council, (2) MS Research Australia, (3) Medical Research Future Fund, (4) Australian Research Council, (5) MS Society, UK, (6) EDMUS and ARSEP Foundations
NONE
NONE
NONE
NONE
NONE
NONE
- From the CORe (T.U., C.M., T.K.), Department of Medicine, the University of Melbourne, VIC, Australia; Department of Neurology and Center of Clinical Neuroscience (T.U., E.K.H., D.H.), Charles University in Prague, 1st Faculty of Medicine and General University Hospital; Department of Radiology (J.K., M.V.), Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Czech Republic; Buffalo Neuroimaging Analysis Center (N.B., M.G.D., R.Z.), Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York; IRCCS (N.B.), Fondazione Don Carlo Gnocchi, Milan, Italy; Center for Biomedical Imaging at Clinical Translational Science Institute (R.Z.), University at Buffalo, State University of New York; and Melbourne MS Centre (T.K.), Department of Neurology, the Royal Melbourne Hospital, VIC, Australia.
- Correspondence
Dr. Uher tomas.uher{at}vfn.cz
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.